Augmedix Reports $10.8M Revenue in Q2 2023

As per the agreement, both companies are sharing the discovery and development costs. The companies will also co-own the drugs developed during their partnership. Image

Amy­lyx out­lined the scope of its Phase 3 de­feat, demon­strat­ing the ex­tent to which its now-with­drawn ALS drug Re­lyvrio failed to sep­a­rate it­self from place­bo.